WO2003035007A3 - Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 - Google Patents

Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 Download PDF

Info

Publication number
WO2003035007A3
WO2003035007A3 PCT/US2002/034456 US0234456W WO03035007A3 WO 2003035007 A3 WO2003035007 A3 WO 2003035007A3 US 0234456 W US0234456 W US 0234456W WO 03035007 A3 WO03035007 A3 WO 03035007A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclooxygenase
expression
activity
compositions exhibiting
synergistic inhibition
Prior art date
Application number
PCT/US2002/034456
Other languages
French (fr)
Other versions
WO2003035007A2 (en
Inventor
John G Babish
Terrence Howell
Linda Pacioretty
Original Assignee
Metaproteomics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ532560A priority Critical patent/NZ532560A/en
Application filed by Metaproteomics Llc filed Critical Metaproteomics Llc
Priority to MXPA04003734A priority patent/MXPA04003734A/en
Priority to EP02784313A priority patent/EP1446136B1/en
Priority to DE60237836T priority patent/DE60237836D1/en
Priority to CA2464334A priority patent/CA2464334C/en
Priority to JP2003537576A priority patent/JP2005506996A/en
Priority to KR10-2004-7006048A priority patent/KR20040054738A/en
Priority to AU2002348096A priority patent/AU2002348096B2/en
Priority to AT02784313T priority patent/ATE482696T1/en
Priority to DK02784313.5T priority patent/DK1446136T3/en
Publication of WO2003035007A2 publication Critical patent/WO2003035007A2/en
Publication of WO2003035007A3 publication Critical patent/WO2003035007A3/en
Priority to AU2008202916A priority patent/AU2008202916B8/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Abstract

A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or derivatives thereof. The composition provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.
PCT/US2002/034456 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 WO2003035007A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2003537576A JP2005506996A (en) 2001-10-26 2002-10-25 Curcuminoid composition exhibiting synergistic inhibition of cyclooxygenase-2 expression and / or activity
MXPA04003734A MXPA04003734A (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2.
EP02784313A EP1446136B1 (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
DE60237836T DE60237836D1 (en) 2001-10-26 2002-10-25 CURCUMINOID COMPOSITIONS WITH SYNERGISTIC INHIBITION OF EXPRESSION AND / OR EFFECT OF CYCLOOXYGENASE-2
CA2464334A CA2464334C (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
NZ532560A NZ532560A (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
KR10-2004-7006048A KR20040054738A (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
DK02784313.5T DK1446136T3 (en) 2001-10-26 2002-10-25 Curcuminoid compositions with synergistic inhibition of the expression and / or activity of cyclooxygenase-2 gene
AT02784313T ATE482696T1 (en) 2001-10-26 2002-10-25 CUCUMINOID COMPOSITIONS WITH SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTION OF CYCLOOXYGENASE-2
AU2002348096A AU2002348096B2 (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
AU2008202916A AU2008202916B8 (en) 2001-10-26 2008-07-02 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activty of cyclooxygenase-2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33506201P 2001-10-26 2001-10-26
US60/335,062 2001-10-26

Publications (2)

Publication Number Publication Date
WO2003035007A2 WO2003035007A2 (en) 2003-05-01
WO2003035007A3 true WO2003035007A3 (en) 2003-09-18

Family

ID=23310091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034456 WO2003035007A2 (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

Country Status (14)

Country Link
US (1) US20030096027A1 (en)
EP (2) EP1446136B1 (en)
JP (3) JP2005506996A (en)
KR (1) KR20040054738A (en)
AT (1) ATE482696T1 (en)
AU (2) AU2002348096B2 (en)
CA (1) CA2464334C (en)
DE (1) DE60237836D1 (en)
DK (1) DK1446136T3 (en)
ES (1) ES2353868T3 (en)
MX (1) MXPA04003734A (en)
NZ (1) NZ532560A (en)
PT (1) PT1446136E (en)
WO (1) WO2003035007A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846115B2 (en) 2001-11-13 2014-09-30 Metaproteomics, Inc. Anti-inflammatory cyclooxygenase inhibitors

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149113A1 (en) 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20020076452A1 (en) * 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
EP1446136B1 (en) * 2001-10-26 2010-09-29 Metaproteomics, LLC Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7279185B2 (en) 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20060233902A1 (en) * 2002-02-14 2006-10-19 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
JP2005529123A (en) * 2002-04-24 2005-09-29 リサーチ ディベロップメント ファンデーション Synergistic effect of nuclear transcriptional regulator NF-κB inhibitor and antitumor agent
EP1523318A4 (en) * 2002-06-24 2007-07-04 Res Dev Foundation Treatment of human multiple myeloma by curcumin
MXPA05004288A (en) * 2002-10-21 2005-08-02 Metaproteomics Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response.
JP2005104951A (en) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd Hypotensive composition, blood vessel flexibility-improving composition, and food imparted with such functions
EP1626731B1 (en) * 2003-05-22 2009-01-21 Metaproteomics, LLC Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
ITMI20031098A1 (en) * 2003-05-30 2004-11-30 Indena Spa USEFUL COMPOUNDS IN ALZHEIMER DISEASE THERAPY AND FORMULATIONS CONTAINING THEM
US7462646B2 (en) * 2003-08-26 2008-12-09 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
JP2005154390A (en) * 2003-11-28 2005-06-16 Morishita Jintan Kk Hepatoprotectant agent
AU2011202586B2 (en) * 2004-02-27 2012-03-22 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
AU2005296565A1 (en) * 2004-10-22 2006-04-27 Kirin Beer Kabushiki Kaisha Transcriptional factor Nrf2 activator and food having the function of the same imparted thereto
AU2005304317A1 (en) * 2004-11-13 2006-05-18 Metaproteomics, Llc Compositions exhibiting inhibition of cyclooxygenase-2
US20080248131A1 (en) * 2005-08-09 2008-10-09 Metaproteomics, Llc Protein Kinase Modulation by Hops and Acacia Products
JP2009518439A (en) * 2005-12-09 2009-05-07 メタプロテオミクス,エルエルシー Protein kinase regulation by hops and acacia products
EP2023747A2 (en) * 2006-05-24 2009-02-18 DSMIP Assets B.V. 3,5-dihydroxy-2,4-cyclohexadienones and their derivatives, dietary compositions and fortified food containing them and their uses
JP2009541326A (en) * 2006-06-20 2009-11-26 メタプロテオミクス, エルエルシー Beta acid-based protein kinase-regulated cancer therapy
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
WO2008048410A2 (en) * 2006-09-19 2008-04-24 Human Biomolecular Research Institute Diagnostic methods and genetic markers for alzheimer disease
MX2009010049A (en) * 2007-03-19 2010-03-04 Metaproteomics Llc Methods and compositions for promoting bone and joint health.
US8192768B2 (en) 2007-04-03 2012-06-05 Laila Impex Synergistic anti-inflammatory and antioxidant dietary supplement compositions
JP2010526882A (en) * 2007-05-11 2010-08-05 メタプロテオミクス, エルエルシー Methods and compositions for detoxifying heavy metals
WO2009066303A2 (en) * 2007-11-22 2009-05-28 Ganga Raju Gokaraju New synergistic phytochemical composition for the treatment of obesity
CA2708613A1 (en) * 2007-12-10 2009-06-18 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
JP2011516492A (en) * 2008-04-02 2011-05-26 メタプロテオミクス, エルエルシー Attenuation of endothelial inflammation and endothelium-monocyte interaction by substituted 1,3-cyclopentadione
EP2274411A4 (en) * 2008-04-11 2016-01-20 Betal Llc Xanthohumol compositions and methods for treating skin diseases or disorders
WO2013100136A1 (en) 2011-12-28 2013-07-04 株式会社マルハニチロ食品 Degranulation inhibitor containing chlorophyll c
JP6163084B2 (en) * 2013-11-11 2017-07-12 キリン株式会社 Composition for preventing, treating and / or improving cognitive function of dementia, and medicine and food using the same
JP6242746B2 (en) * 2014-05-26 2017-12-06 キリン株式会社 Medicines, foods, and compositions that improve memory learning function
CN107582962A (en) * 2017-06-01 2018-01-16 合肥远志医药科技开发有限公司 A kind of formula and its extraction process for atrophic gastritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494668A (en) * 1994-07-11 1996-02-27 Patwardhan; Bhushan Method of treating musculoskeletal disease and a novel composition therefor
US6143303A (en) * 1999-08-14 2000-11-07 Janakiram; Chodavarapu Analgesic anti-inflammatory composition and method of preparing from dodonaea sp
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07149628A (en) * 1993-11-30 1995-06-13 Suntory Ltd Improver for lipid metabolism
JPH0873369A (en) * 1994-09-01 1996-03-19 Fuairudo:Kk Tea for health
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
DE10031955A1 (en) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing them
EP1446136B1 (en) * 2001-10-26 2010-09-29 Metaproteomics, LLC Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494668A (en) * 1994-07-11 1996-02-27 Patwardhan; Bhushan Method of treating musculoskeletal disease and a novel composition therefor
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US6143303A (en) * 1999-08-14 2000-11-07 Janakiram; Chodavarapu Analgesic anti-inflammatory composition and method of preparing from dodonaea sp
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846115B2 (en) 2001-11-13 2014-09-30 Metaproteomics, Inc. Anti-inflammatory cyclooxygenase inhibitors

Also Published As

Publication number Publication date
AU2008202916B2 (en) 2010-06-03
EP2253314A2 (en) 2010-11-24
DK1446136T3 (en) 2011-01-10
NZ532560A (en) 2005-02-25
JP2011093918A (en) 2011-05-12
MXPA04003734A (en) 2005-06-20
PT1446136E (en) 2010-12-29
EP1446136A4 (en) 2007-01-10
EP2253314A3 (en) 2012-08-01
AU2008202916A1 (en) 2008-07-24
CA2464334C (en) 2012-01-10
US20030096027A1 (en) 2003-05-22
AU2002348096B2 (en) 2008-04-03
DE60237836D1 (en) 2010-11-11
WO2003035007A2 (en) 2003-05-01
AU2008202916B8 (en) 2010-06-10
JP2005506996A (en) 2005-03-10
CA2464334A1 (en) 2003-05-01
ATE482696T1 (en) 2010-10-15
KR20040054738A (en) 2004-06-25
EP1446136B1 (en) 2010-09-29
JP2011068680A (en) 2011-04-07
EP1446136A2 (en) 2004-08-18
ES2353868T3 (en) 2011-03-07

Similar Documents

Publication Publication Date Title
WO2003035007A3 (en) Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
NL350084I2 (en) Sedaxane and Fludioxonil
HUP0303955A2 (en) Herbicidal compositions comprising benzoylcyclohexanediones and safeners and a method for their use
WO2001015680A8 (en) Composition for treatment of infections of humans and animals
NO996269L (en) Quinoline-indole antimicrobial agents, as well as the use and mixtures thereof
NO20080801L (en) Aerosol formulation for inhalation of beta agonists
EP1411959A4 (en) Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
CA2369975A1 (en) Deodorizing preparations comprising water soluble beta-(1,3)glucans
FI963232A0 (en) Acidified nitrite as an antimicrobial agent
HUP0102415A2 (en) Oxime derivatives, intermediates, preparation thereof and agricultural chemicals containing the same
DE60041753D1 (en) MEDICAMENT FOR THE TREATMENT OF C. PNEUMONIAE INFECTIONS
WO2005074986A3 (en) Bioactive species capable of interfering with a microbial toxin-antitoxin complex and methods for evaluation and use of said bioactive species
ATE409065T1 (en) INHIBITORS OF 17 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES
CA2271162A1 (en) Stearidonic acid compositions and uses thereof
ES2043671T3 (en) A COMPOSITION FOR APPLICATION TO A PLANT SITE.
WO2002091858A8 (en) Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
TWI256292B (en) Reduction inhibitory agent for active oxygen eliminating activity
NO20055518L (en) 5-hydroxyindoles with N-oxide groups, use thereof as phosphodiesterase 4 inhibitor
HUP9801881A3 (en) Hydroximic acid derivatives, preparation and use thereof, pesticide and fungicide compositions containing these compounds as active ingredients
WO2004069173A3 (en) Methods for modulating an inflammatory response
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
WO2003102206A3 (en) Sgk and nedd used as diagnostic and therapeutic targets
BR0309433A (en) Dry Yeast Composition
WO2002069720A3 (en) Biopesticide compositions
FR2379982A1 (en) COMPOSITION PESTICIDE WITH SYNERGIC EFFECT INCLUDING A PYRETHROID INSECTICIDE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2464334

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/003734

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002348096

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 532560

Country of ref document: NZ

Ref document number: 1020047006048

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003537576

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002784313

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002784313

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 532560

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 532560

Country of ref document: NZ